Reason for request
-
Clinical Benefit
Substantial |
Superficial, non-recurrent basal cell carcinoma of the trunk, limbs and neck : substantial AB in inoperable patients with extensive or multiple lesions or lesions that are difficult to access surgically. Non-pigmented squamous cell carcinoma in situ (Bowen’s disease) in immunocompetent subjects when surgery is not possible: substantial AB. |
Moderate |
Multiple, thin or non-hyperkeratotic and non-pigmented actinic keratoses of the scalp : moderate AB. Superficial, non-recurrent basal cell carcinoma of the trunk, limbs and neck : moderate AB in other cases |
Clinical Added Value
minor |
In superficial, non-recurrent basal cell carcinoma of the trunk, limbs and neck, METVIXIA : - provides a minor improvement in actual benefit (level IV) in inoperable patients with extensive or multiple lesions or lesions that are difficult to access surgically ; - does not provide any improvement in actual benefit (level V) in other cases. METVIXIA provides a minor improvement in actual benefit (level IV) in the treatment of non-pigmented squamous cell carcinoma in situ (Bowen’s disease) in immunocompetent subjects when surgery is not possible. |
no clinical added value |
The improvement in actual benefit provided by METVIXIA is unchanged (level V, non-existent) in the treatment of thin or non-hyperkeratotic and non-pigmented actinic keratoses of the face and scalp. |